Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 119

Sort by

Sort Order Select

Journal Articles

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Blood (2024) 144 (9): 1010–1021.

https://doi.org/10.1182/blood.2024025106

Published: 2024

Includes: Supplemental data

Journal Articles

Introduction to a review series on oncogenic signaling and immune evasion in hematologic malignancies

Robert Zeiser

Blood (2024) 143 (26): 2679.

https://doi.org/10.1182/blood.2024023825

Published: 2024

Journal Articles

The role of the MDM2/p53 axis in antitumor immune responses

Tilman Brummer, Robert Zeiser

Blood (2024) 143 (26): 2701–2709.

https://doi.org/10.1182/blood.2023020731

Published: 2024

Journal Articles

CSF1R inhibition promotes neuroinflammation and behavioral deficits during graft-versus-host disease in mice

Rachael C. Adams, Dylan Carter-Cusack, Genesis T. Llanes, Christopher R. Hunter, Janaki Manoja Vinnakota, Marc J. Ruitenberg, Jana Vukovic, Patrick Bertolino, Kirat K. Chand, Julie A. Wixey, Samuel P. Nayler, Geoffrey R. Hill, Scott N. Furlan, Robert Zeiser, Kelli P. A. MacDonald

Blood (2024) 143 (10): 912–929.

https://doi.org/10.1182/blood.2023022040

Published: 2024

Includes: Supplemental data

Journal Articles

Prevention of CMV/EBV Reactivation By Double-Specific T Cells in Patients after Allogeneic Stem Cell Transplantation: Results from the Randomized Phase I/IIa Multivir-01 Study

Blood (2023) 142 (Supplement 1): 6849.

https://doi.org/10.1182/blood-2023-178273

Published: 2023

Journal Articles

Long-Term Follow-up of AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after Primary Induction Failure

Miriam Mozaffari Jovein, Gabriele Ihorst, Jesus Duque Afonso, Ralph Wäsch, Claudia Wehr, Hartmut Bertz, Justus Duyster, Robert Zeiser, Jürgen Finke, Florian Scherer

Blood (2023) 142 (Supplement 1): 3588.

https://doi.org/10.1182/blood-2023-179103

Published: 2023

Journal Articles

Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study

Blood (2023) 142 (Supplement 1): 776.

https://doi.org/10.1182/blood-2023-181900

Published: 2023

Journal Articles

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Robert Zeiser, Domenico Russo, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Nada Hamad, Xuechan Li, Maanasa Gowda, Tommaso Stefanelli, Stephanie J. Lee, Takanori Teshima, Franco Locatelli

Blood (2023) 142 (Supplement 1): 654.

https://doi.org/10.1182/blood-2023-172590

Published: 2023

Journal Articles

Spatially Resolved Transcriptomics Unveils Unique T-Cell Dysfunctional States and Prognostic Gene Expression Signatures in TP53 -Mutated Acute Myeloid Leukemia

Jayakumar Vadakekolathu, Heidi Altmann, Manja Wobus, Malte von Bonin, Marc Schmitz, Gustavo B. Baretton, Robert Zeiser, Martin Bornhäuser, Sergio Rutella

Blood (2023) 142 (Supplement 1): 291.

https://doi.org/10.1182/blood-2023-174871

Published: 2023

Journal Articles

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Janaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, Chintan Chhatbar, Rachael C Adams, Daniel Erny, Sandra Duquesne, Nadia El Khawanky, Henrike Salié, Dimitrios Athanassopoulos, Lukas Braun, Dominik Schmidt, Viktor Fetsch, Rebeka N. Javorniczky, Jenny N.H.G Ho, Reinhard Marks, Ralph Wäsch, Federico Simonetta, Geoffroy Andrieux, Dietmar Pfeifer, Gianni Monaco, Christian Capitini, Terry J. Fry, Thomas Blank, Bruce R Blazar, Eva-Maria Wagner Drouet, Matthias Theobald, Clemens Sommer, Matthias Stelljes, Christian Reicherts, Astrid Jeibmann, Jens Schittenhelm, Camelia-Maria Monoranu, Andreas Rosenwald, K. Martin Kortüm, Leo Rasche, Hermann Einsele, Philipp Tobias Meyer, Joachim Brumberg, Andreas Mackensen, Michael von Bergwelt-Baildon, Roland Coras, Nathalie L. Albert, Laura M. Bartos, Matthias Brendel, Adrien Holzgreve, Melanie Boerries, Crystal L. Mackall, Justus Duyster, Natalie Koehler, Felix Strübing, Bertram Bengsch, Marco Ruella, Marion Subklewe, Louisa von Baumgarten, Saar Gill, Marco Prinz, Robert Zeiser

Blood (2023) 142 (Supplement 1): 100.

https://doi.org/10.1182/blood-2023-184867

Published: 2023

Journal Articles

CSF1R Inhibition Promotes Neuroinflammation and Behavioural Deficits during Graft-Versus-Host Disease in Mice

Rachael C Adams, Dylan Carter-Cusack, Genesis T Llanes, Christopher R Hunter, Janaki Manoja Vinnakota, Marc Ruitenberg, Jana Vukovic, Patrick Bertolino, Kirat K. Chand, Julie A. Wixey, Samuel P Nayler, Geoffrey R Hill, Scott N Furlan, Robert Zeiser, Kelli PA MacDonald

Blood (2023) 142 (Supplement 1): 2052.

https://doi.org/10.1182/blood-2023-184841

Published: 2023

Journal Articles

The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd

Blood (2023) 142 (Supplement 1): 3576.

https://doi.org/10.1182/blood-2023-182300

Published: 2023

Journal Articles

Real-World Data Suggest Effectiveness of Allogeneic Mesenchymal Stromal (MSC-FFM) Cells in Ruxolitinib-Refractory Acute Graft-Versus-Host Disease

Blood (2023) 142 (Supplement 1): 4927.

https://doi.org/10.1182/blood-2023-174492

Published: 2023

Journal Articles

TIM-3 Inhibitor Sabatolimab for Patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) Detected after Allogeneic Stem Cell Transplantation (AlloSCT): Preliminary Findings from the Phase Ib/II Stimulus-AML2 Study

Robert Zeiser, Raynier Devillier, Maria Caterina Mico', David Valcarcel, Simon Call, Christian Niederwieser, Claire Nourry, Yunnan Xu, Thierry Medts, Nathalie Guichard, Hans D. Menssen, Nicola Polverelli

Blood (2023) 142 (Supplement 1): 59.

https://doi.org/10.1182/blood-2023-180876

Published: 2023

Journal Articles

Novel developments in the prophylaxis and treatment of acute GVHD

Omer Jamy, Robert Zeiser, Yi-Bin Chen

Blood (2023) 142 (12): 1037–1046.

https://doi.org/10.1182/blood.2023020073

Published: 2023

Journal Articles

Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms

Blood (2023) 141 (23): 2824–2840.

https://doi.org/10.1182/blood.2022015653

Published: 2023

Includes: Supplemental data

Journal Articles

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Gerard Socié, Dietger Niederwieser, Nikolas von Bubnoff, Mohamad Mohty, Jeff Szer, Reuven Or, James Garrett, Anirudh Prahallad, Celine Wilke, Robert Zeiser

Blood (2023) 141 (22): 2771–2779.

https://doi.org/10.1182/blood.2022018579

Published: 2023

Includes: Supplemental data

Journal Articles

Introduction to a How I Treat series on management of high-risk patients following allogeneic transplant

Robert Zeiser

Blood (2023) 141 (1): 1.

https://doi.org/10.1182/blood.2022018003

Published: 2023

Journal Articles

Effective and Safe Immune Checkpoint Blockade Induces Complete Responses in Murine PTCL Model of ALCL

Linda Gräßel, Teresa Poggio, Geoffroy Andrieux, Irene Gonzalez-Menendez, Stefanie Kreutmair, Cornelius Miething, Federico Bonofiglio, Ivonne Aidee Montes Mojarro, Marie Follo, Dietmar Pfeifer, Falko Fend, Leticia Quintanilla-Martinez, Robert Zeiser, Suzanne Turner, Melanie Börries, Justus Duyster, Anna Lena Illert

Blood (2022) 140 (Supplement 1): 6466–6467.

https://doi.org/10.1182/blood-2022-168777

Published: 2022

Journal Articles

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Annie Im, Daniel Wolff, Corey Cutler, Robert Zeiser, Nirav N. Shah, Ming Tony Tan, Jaime Sanz, Haris Ali, Giuseppe Milone, Arjun D. Law, Domenico Russo, Eva-Maria Wagner, Olga Ivanova, Kevin Hou, Maureen Bleam, Rodica Morariu-Zamfir, Steven Z Pavletic

Blood (2022) 140 (Supplement 1): 1870–1871.

https://doi.org/10.1182/blood-2022-169605

Published: 2022

NARROW

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Introduction to a review series on oncogenic signaling and immune evasion in hematologic malignancies

The role of the MDM2/p53 axis in antitumor immune responses

CSF1R inhibition promotes neuroinflammation and behavioral deficits during graft-versus-host disease in mice

Prevention of CMV/EBV Reactivation By Double-Specific T Cells in Patients after Allogeneic Stem Cell Transplantation: Results from the Randomized Phase I/IIa Multivir-01 Study

Long-Term Follow-up of AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after Primary Induction Failure

Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Spatially Resolved Transcriptomics Unveils Unique T-Cell Dysfunctional States and Prognostic Gene Expression Signatures in TP53 -Mutated Acute Myeloid Leukemia

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

CSF1R Inhibition Promotes Neuroinflammation and Behavioural Deficits during Graft-Versus-Host Disease in Mice

The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd

Real-World Data Suggest Effectiveness of Allogeneic Mesenchymal Stromal (MSC-FFM) Cells in Ruxolitinib-Refractory Acute Graft-Versus-Host Disease

TIM-3 Inhibitor Sabatolimab for Patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) Detected after Allogeneic Stem Cell Transplantation (AlloSCT): Preliminary Findings from the Phase Ib/II Stimulus-AML2 Study

Novel developments in the prophylaxis and treatment of acute GVHD

Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Introduction to a How I Treat series on management of high-risk patients following allogeneic transplant

Effective and Safe Immune Checkpoint Blockade Induces Complete Responses in Murine PTCL Model of ALCL

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only